Mito-LND

• CAT Number: I044536
• CAS Number: 2361564-49-8
• Molecular Formula: C43H45BrCl2N3OP
• Molecular Weight: 801.62
• Purity: ≥95%
• Synonyms: 10-[[1-[(2,4-dichlorophenyl)methyl]indazole-3-carbonyl]amino]decyl-triphenylphosphanium;bromide
• InChI: InChI=1S/C43H44Cl2N3OP.BrH/c44-35-29-28-34(40(45)32-35)33-48-41-27-17-16-26-39(41)42(47-48)43(49)46-30-18-5-3-1-2-4-6-19-31-50(36-20-10-7-11-21-36,37-22-12-8-13-23-37)38-24-14-9-15-25-38;/h7-17,20-29,32H,1-6,18-19,30-31,33H2;1H
• InChIKey: XRSSFQSESARZNG-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)[P+](CCCCCCCCCCNC(=O)C2=NN(C3=CC=CC=C32)CC4=C(C=C(C=C4)Cl)Cl)(C5=CC=CC=C5)C6=CC=CC=C6.[Br-]

Mito-LND (Cat No.:I044536) is a modified derivative of lonidamine designed to selectively accumulate in mitochondria by conjugation with a triphenylphosphonium (TPP⁺) moiety. This targeting enhances its ability to disrupt mitochondrial metabolism, particularly by inhibiting glycolysis and oxidative phosphorylation, leading to energy depletion and induction of apoptosis in cancer cells. Mito-LND has demonstrated potent anti-tumor activity in preclinical models, especially against brain tumors and other highly metabolic cancers. Its selective mitochondrial accumulation reduces systemic toxicity, making it a promising candidate for mitochondrial-targeted cancer therapy and metabolic reprogramming studies.